Xilio Therapeutics (XLO) Peer Comparison

$9.00

$-0.02 (-0.22%)

As on 04-Sep-2026 16:00EDT

Market cap

$59 Mln

Revenue (TTM)

$64 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	59	16,504	17,747	14,622	12,501
Revenue ($ Mln)	64	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-21.83	491.50	755.85	860.62	-325.10
Net Margin (%)	-34.06	17.67	71.69	35.33	-25.32
RoE (%)	-40.60	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	0.82	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	64.09	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	1.01	1,982.07	103.47	85.67	109.42
Gross Profit	42.23	760.62	588.53	2,236.43	902.26
Operating Expenses	95.12	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-31.37	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-21.83	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-21.83	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	72.26	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	47.79	187.89	384.48	288.55	346.72
Current Liabilities	34.20	1,435.43	464.70	361.93	374.20
Total Liabilities	154.69	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	8.79	1,006.90	895.24	1,243.41	45.47
Current Assets	145.47	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	154.69	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	6.30	120.10	449.89	165.93	347.75
Net Current Assets	111.27	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-4.99	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-0.52	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	87.78	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-103.10	53.56	-30.01	32.82	-31.49
ROE (%)	-40.60	110.09	163.18	42.98	-57.72
ROA (%)	-11.63	15.64	31.68	29.32	-22.97
EBIT Margin (%)	-34.06	21.13	5.73	31.04	-18.97
Net Margin (%)	-34.06	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	327.25	24.67	114.85	9.23	149.04
EBIT Growth (%)	61.71	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	61.17	17.50	378.76	42.89	-15.32
EPS Growth (%)	85.46	26.84	353.27	50.42	-0.64
Book Value Growth (%)	95.03	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-1.53	36.06	-59.76	15.79	-45.32
Price / Book Value	0.82	38.18	10.51	7.95	23.94
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	3.48	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.02	0.00	0.05	0.00	0.00
Current Ratio	4.25	0.73	2.99	3.46	3.20
Quick Ratio	4.25	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-9.32

Operating Efficiency Ratios

	Xilio Therapeutics (XLO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	9.36	15.88	21.25	13.74	14.98
Asset Turnover	0.34	0.89	0.44	0.83	0.91
Receivable days	41.73	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	680.49	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly